Rare and Insidious Toxicities from New Combination Therapies in Metastatic Renal Cell Cancer: Lessons Learned from Real-Practice

The advent of immune checkpoint inhibitors in combination with multitarget tyrosine kinase inhibitors has become a standard first-line treatment for metastatic renal cell cancer. Along with survival improvement, new toxicities have emerged. Such adverse events are still complex to be managed and som...

Descripción completa

Detalles Bibliográficos
Autores principales: Dri, Arianna, Garattini, Silvio Ken, Cinausero, Marika, Macerelli, Marianna, Fanelli, Martina, Puglisi, Fabio, Fasola, Gianpiero, Ermacora, Paola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600961/
https://www.ncbi.nlm.nih.gov/pubmed/36290810
http://dx.doi.org/10.3390/curroncol29100533

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600961/
https://www.ncbi.nlm.nih.gov/pubmed/36290810
http://dx.doi.org/10.3390/curroncol29100533

Ejemplares similares